Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy
Germ Cell Tumor
DRUG: Rolapitant|DRUG: Palonosetron|DRUG: Olanzapine|DRUG: Dexamethasone
Complete Response Rate, Determine the complete response (CR) rate defined as no emesis and no use of rescue medications in germ cell tumor patients treated with rolapitant plus Olanzapine in combination with palonosetron a 5HT3RA and dexamethasone on Cycle 1 Day 1 through Day 8, 8 Days
Complete Response Rate: Acute Phase, Determine the CR rate in the acute phase (Days 1-5) defined as no emesis and no use of rescue medications in germ cell tumor patients treated with rolapitant plus Olanzapine in combination with palonosetron a 5HT3RA and dexamethasone on Cycle 1 Day 1 through Day 5, 5 Days|Complete Response Rate: Delayed Phase, Determine the CR rate in the delayed phase (Days 6-8) defined as no emesis and no use of rescue medications in germ cell tumor patients treated with rolapitant plus Olanzapine in combination with palonosetron a 5HT3RA and dexamethasone on Cycle 1 Day 6 through Day 8, 2 Days|Frequency, intensity, and duration of nausea, Determine the frequency, intensity and duration of nausea on Days 1-8 in Cycle 1. The frequency, intensity and duration of nausea will be captured via daily self-assessment patient logs., 8 Days|Frequency of vomiting or retching., Determine the frequency, intensity and duration of vomiting or retching on Days 1-8 in Cycle 1. The frequency of vomiting and retching will be captured via daily self-assessment patient logs., 8 Days|Intensity of Vomiting or retching., Determine the intensity of vomiting or retching on Days 1-8 in Cycle 1. The intensity of vomiting and retching will be captured via daily self-assessment patient logs., 8 Days|Duration of Vomiting or retching, Determine the duration of vomiting or retching on Days 1-8 in Cycle 1. The duration of vomiting and retching will be captured via daily self-assessment patient logs., 8 Days|Rate of no nausea, Determine the rate of no nausea defined as \< 5mm on a 0-100mm visual analog scale (VAS) on Days 1-5 and Days 6-8 on Cycle 1, 8 Days|Use of rescue medications, Describe the use of rescue medications as defined in the protocol, 8 Days|Assess adverse events of regimen using CTCAE v4., Safety and toxicity will be assessed using CTCAE v4, 8 Days
Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy